Agennix AG

Top Of The Market Indicator Ask any European private biotech company just a year ago on its plans for fundraising and a NASDAQ IPO would probably have figured highly in the answer. Since the start of

At an extraordinary general meeting (EGM) on 22 May, Agennix shareholders voted in favor of the liquidation of the company. It will be dissolved by 31 May 2013, with liquidation slated to take at leas

Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. The U.S./German biotech Agennix AG announced

German biotech Agennix AG is to cut its workforce by 55%, or around 37 employees, and close its facility in Houston, Texas, following the failure of its lead compound, talactoferrin, in the Phase